(Q38209438)

31 August 2017

title

Defining phenotypes in asthma: a step towards personalized medicine (English)

1 reference

31 August 2017

0 references

personalized medicine

1 reference

Kian Fan Chung

1

0 references

publication date

1 May 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

74

1 reference

31 August 2017

issue

7

1 reference

31 August 2017

page(s)

719-728

1 reference

Clinical phenotypes of asthma

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Challenges in identifying asthma subgroups using unsupervised statistical learning techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Cluster analysis and clinical asthma phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Identifying adult asthma phenotypes using a clustering approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Identification of asthma clusters in two independent Korean adult asthma cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Asthma phenotypes in Japanese adults - their associations with the CCL5 and ADRB2 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Application of the asthma phenotype algorithm from the Severe Asthma Research Program to an urban population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Childhood asthma clusters and response to therapy in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Identification of subtypes of refractory asthma in Korean patients by cluster analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Cluster analysis of obesity and asthma phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Three phenotypes of adult-onset asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Ten-year follow-up of cluster-based asthma phenotypes in adults. A pooled analysis of three cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Effects of steroid therapy on inflammatory cell subtypes in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Effects of oral prednisone on sputum eosinophils and cytokines in patients with severe refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Effects of montelukast and beclomethasone on airway function and asthma control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Body mass and glucocorticoid response in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Characterization of factors associated with systemic corticosteroid use in severe asthma: data from the Severe Asthma Research Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Corticosteroid insensitivity of chemokine expression in airway smooth muscle of patients with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Association of Glucocorticoid Insensitivity with Increased Expression of Glucocorticoid Receptor β

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

A large subgroup of mild-to-moderate asthma is persistently noneosinophilic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Bacteria in sputum of stable severe asthma and increased airway wall thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Differences in airway cytokine profile in severe asthma compared to moderate asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

T-helper type 2-driven inflammation defines major subphenotypes of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

New targets for drug development in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Innate and adaptive immune responses in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

New treatments for severe treatment-resistant asthma: targeting the right patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Reslizumab for Poorly Controlled, Eosinophilic Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Targeting interleukin-4 in asthma: lost in translation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Dupilumab in persistent asthma with elevated eosinophil levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Lebrikizumab Treatment in Adults with Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Clarithromycin targets neutrophilic airway inflammation in refractory asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

The investigation of severe asthma to define phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Inflammatory biomarkers in severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Epigenetics in asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

A protein interaction network associated with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

An integrative systems biology approach to understanding pulmonary diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Systems biology: personalized medicine for the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

The Path to Personalized Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0213-9

Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples

21 January 2018

1 reference

12 December 2020

Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society

1 reference

12 December 2020

Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages

1 reference

12 December 2020

Sputum hydrogen sulfide as a novel biomarker of obstructive neutrophilic asthma

1 reference

12 December 2020

Neutrophilic inflammation in severe persistent asthma

1 reference

12 December 2020

Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial

1 reference

12 December 2020

A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma

1 reference

12 December 2020

Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respira

1 reference

12 December 2020

10.1007/S40265-014-0213-9

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1053620756

0 references

1 reference